- Home
- AIRT vs INMB Comparison
AIRT vs INMB Comparison
Compare AIRT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- INMB
- Stock Information
- Founded
- AIRT 1980
- INMB 2015
- Country
- AIRT United States
- INMB United States
- Employees
- AIRT N/A
- INMB N/A
- Industry
- AIRT Air Freight/Delivery Services
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- INMB Health Care
- Exchange
- AIRT Nasdaq
- INMB Nasdaq
- Market Cap
- AIRT 59.6M
- INMB 53.4M
- IPO Year
- AIRT N/A
- INMB 2019
- Fundamental
- Price
- AIRT $24.46
- INMB $1.91
- Analyst Decision
- AIRT
- INMB Buy
- Analyst Count
- AIRT 0
- INMB 4
- Target Price
- AIRT N/A
- INMB $9.53
- AVG Volume (30 Days)
- AIRT 1.2K
- INMB 822.2K
- Earning Date
- AIRT 11-11-2025
- INMB 10-30-2025
- Dividend Yield
- AIRT N/A
- INMB N/A
- EPS Growth
- AIRT N/A
- INMB N/A
- EPS
- AIRT N/A
- INMB N/A
- Revenue
- AIRT $296,309,000.00
- INMB $50,000.00
- Revenue This Year
- AIRT N/A
- INMB $142.83
- Revenue Next Year
- AIRT N/A
- INMB $14,780.90
- P/E Ratio
- AIRT N/A
- INMB N/A
- Revenue Growth
- AIRT 5.14
- INMB N/A
- 52 Week Low
- AIRT $14.56
- INMB $1.71
- 52 Week High
- AIRT $26.70
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- AIRT 55.22
- INMB 38.01
- Support Level
- AIRT $22.63
- INMB $1.71
- Resistance Level
- AIRT $26.37
- INMB $2.12
- Average True Range (ATR)
- AIRT 0.33
- INMB 0.12
- MACD
- AIRT 0.12
- INMB 0.04
- Stochastic Oscillator
- AIRT 53.53
- INMB 45.45
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.